LEADER 01217nam  2200409   450 
001 9910586648303321
005 20221018184855.0
010   $a1-83969-054-2
035   $a(CKB)4950000000722046
035   $a(NjHacI)994950000000722046
035   $a(EXLCZ)994950000000722046
100   $a20221018d2022      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aAntiphospholipid syndrome $erecent advances in clinical and basic aspects /$fedited by Polona Z?igon
210  1$aLondon, England :$cIntechOpen,$d[2022]
210  4$dİ2022
215   $a1 online resource (142 pages)
311   $a1-83969-053-4 
517   $aAntiphospholipid Syndrome 
606   $aAntiphospholipid syndrome
606   $aImmunologic diseases
606   $aPhospholipid antibodies
615  0$aAntiphospholipid syndrome.
615  0$aImmunologic diseases.
615  0$aPhospholipid antibodies.
676   $a616.978
702   $aZ?igon$b Polona
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910586648303321
996   $aAntiphospholipid Syndrome$91551273
997   $aUNINA